By Stephen Nakrosis

 

The Janssen Pharmaceutical Cos. of Johnson & Johnson (JNJ) said Wednesday data from a phase 3 study showed a combination pf Darzalex, or daratumumab, and lenalidomide and dexamethasone resulted in a significant increase in progression-free survival in certain multiple myeloma patients.

The study results were published in the New England Journal of Medicine.

Janssen said the data, which came from data from the randomized, open-label Phase 3 MAIA study, indicated the Darzalex combination "resulted in a significant increase in progression-free survival in patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation."

Study results demonstrated that at a median follow-up of 28 months the treatment reduced the risk of disease progression or death by 44% in patients with newly diagnosed multiple myeloma who are ineligible for ASCT.

The safety of the combination in this patient population was consistent with previously reported studies, Janssen said.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

May 29, 2019 18:05 ET (22:05 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024 Plus de graphiques de la Bourse Johnson and Johnson